AsianScientist (Feb. 14, 2017) – Takeda Pharmaceutical Company Limited has donated US$1 million to support groundbreaking science in immuno-oncology at the Koch Institute. The donation will support the research currently being done at the Koch Institute for Integrative Cancer Research over the next two years.
“Takeda embraces innovative science both inside and outside of our organization, and as part of our commitment to patients with cancer, we look to support academic institutions that are leading research in immuno-oncology,” said Dr. Christopher Arendt, Immunology Discovery Lead at Takeda.
“The Koch Institute was created to promote the best in science and engineering to develop new approaches in the fight against cancer. Immuno-oncology is a major focus of our efforts, and we are grateful to Takeda for its support in this important area of research,” said Dr. Tyler Jacks, Director, Koch Institute for Integrative Cancer Research.
Investigators at the Koch Institute are exploring the relationship between the immune system and cancer in animal models and human patients to improve immune responses to cancer. The Koch Institute works on the development of drug delivery tools, new methods for analyzing cellular immune responses and therapies based on engaging both the innate and the adaptive immune response, including therapeutic and preventative vaccines, as well as therapeutic antibodies through state-of-the art protein engineering methods.
———
Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
